Aortech Share Discussion Threads

[greedy rooster] 05/9/2018 11:45

I agree. Won't take much to get these moving again. So much potential.

[bones] 05/9/2018 09:08

Eddie McDaid is an ex-CEO of AOR (not the one sued!) who is very much on AOR’s side and was I understand part of the team that helped in the litigation against Maguire. He is otherwise retired I believe and my guess is that he has sold his shares to Clive Titcomb. A friendly deal in other words.

The numbers from the recent group of holdings RNS’s suggest that Titcomb acquired 426k from June to August and McDaid had 557k before his sales leaving maybe 130k. Chances are that he has sold the lot (as Stig suggests) which would take Titcomb up to near 6% but the last lot might not trigger another RNS as McDaid went under 3% on this latest RNS.

So I reckon the shares have stayed in sticky, friendly hands and have not disrupted the price greatly.

[semper vigilans] 05/9/2018 07:47

Nearly eight weeks after the event- the reporting of these events is still a bit lax on AIM.
Hopefully this won’t do much damage to the SP, but I bet he wished he’d kept them all now.

[the stigologist] 05/9/2018 07:46

So he had 10% of 5.5m i.e. 550k
Went to 2.98% of 14.6m i.e. 430k
so sold 120k ish

however this LATE notification is contrary to AIM rules so basically McDaid deliberately/accidentally failed to make adequate notification

you can make your own inference but mine would be that if you're a big seller you'd want to do it quietly so as not to cause a buyer's strike tanking the share price as you sell down to ZERO

my assumption would be McDaid was the seller who has been capping the share price rises and is probably at or close to ZERO now

good we have got rid of such an overhang

[investordave] 05/9/2018 07:44

I wonder how the market will react? The transaction doesn't seem to be significant to me.

[langland] 05/9/2018 07:39

Looks like he has sold about 120/30k shares.

[someuwin] 05/9/2018 07:21

...Actually, the total number of shares in issue increased from 5.5m to 14.6m due to the placing, So perhaps he hasn't sold any?

[someuwin] 05/9/2018 07:17

So, Today's RNS is notification that ex-ceo McDaid has reduced from 10% to under 3%. On July 16th.

[blueball] 04/9/2018 14:43

Buy the dips Dave.

[someuwin] 04/9/2018 14:42

More buys than sells now.

[investordave] 04/9/2018 14:15

I see someone has just sold £34 in shares. Whoever you are, make sure you spend the money wisely. Probably got a little over £20 after dealing fees.

[bones] 03/9/2018 18:40

Lol, Netcurtains, you raise an amusing point. I wonder how many vegans/vegetarians are walking around today with a sliver of cow or pig stitched inside them. Unlikely it crosses a person's mind (vegan or otherwise) when they are under the knife for heart repair. Elast-Eon is considered to be a fabulous substitute for animal tissue in grafts and patches at a time now when the surgery is far more common with technique advances and with demographic changes. The benefit is replacing something in short supply as well as certain hygiene issues (animal tissue) with something long proven to work with human tissue.With AorTech developing these with RUA Medical, it's hard to see the products not being approved by the medical authorities in the next year or two. That's certainly AOR's aim.The heart valve with VFT is clearly a longer project but the prize is huge.

[busterdog2] 03/9/2018 13:27

Lol. Heard that one before.

[blueball] 03/9/2018 13:09

Don't worry this will be 100p plus by the year end.

[greedy rooster] 03/9/2018 12:24

More value then, thanks NC. Niche, disruptive, needed - not bad in a world where most investments offer little value.

[netcurtains] 03/9/2018 11:49

Greedy Rooster: I'm not 100% certain but AOR are suggesting that their products are animal free - eg suitable for Californian vegan investors and ethical etc

AorTech has identified two device categories that currently rely on abattoir-sourced animal by-products. These are pericardial patches and large bore vascular grafts. Replacing animal tissue with a world leading bio-stable polymer

[greedy rooster] 03/9/2018 11:26

No doubt they'll do all the hard graft (no pun intended) and will get bought out at a lofty premium, madness to dump this at current levels.

[netcurtains] 03/9/2018 10:51

Polymeric Heart Valves

AorTech has the opportunity to transform the global treatment of heart disease by delivering a synthetic heart valve that will be durable, so reducing the need for future replacement and should not require lifelong drug treatment. As well as these clear clinical advantages, the manufacturing costs of a synthetic valve will be considerably less than those of current valve technology making this a potentially disruptive advance in heart valve surgery. AorTech's historic investment and progress to date dramatically reduces both the time and cost of preparing a novel valve for human trial.

When it initially developed a synthetic valve, AorTech was ahead of the market, but the global heart valve market (valued at some US$5 billion) is now in need of new technology, enhancing the opportunities available to AorTech.

Medical Textiles

AorTech has identified two device categories that currently rely on abattoir-sourced animal by-products. These are pericardial patches and large bore vascular grafts. Replacing animal tissue with a world leading bio-stable polymer will reduce manufacturing costs, eliminate animal by-product sourcing risk and improve product sterilisation options and performance. The initial products to be developed are targeted to be ready for human use within two years due to the acceptance of Elast-Eon™ in long-term implants.

Patches

The currently available technology comprises either animal tissue or textile (PTFE) material. Each material is compromised by either suffering from calcification or subject to tissue ingrowth leading to adhesion. AorTech will develop an Elast-Eon™ based product that should avoid these problems and address a market that is suffering a lack of supply of animal sourced products.



Vascular Grafts

The currently available technology comprises tightly woven PTFE grafts or softer polyester grafts sealed with animal-sourced material, limiting sterilisation options. AorTech will develop new graft technology replicating current graft performance, but utilising Elast-Eon™ as a sealing agent. The graft will be made available as a direct surgical implant and as a component to other medical device companies, particularly for incorporation into valved conduits for tissue based valves that require wet sterilisation.

Business Model

The medical device industry is highly regulated and requires a significant amount of infrastructure to operate to the various standards required. Setting up a development facility with a view to manufacturing devices would require not only substantial investment in people but a lengthy time commitment in obtaining certification and establishing systems.



AorTech had previously made a strategic decision to exit polymer manufacture and the relationship with Biomerics enabled a more attractive manufacturing model to be put in place. Having found this business model to operate well, AorTech has sought to develop its business by working in partnership with well-established businesses that not only have the necessary infrastructure in place but can develop our new products more economically and faster than the Company could by setting up itself. The business model is, therefore, to keep corporate infrastructure costs to a minimum by outsourcing to experts, thus minimising risk and maximising return on investment.

[ny boy] 03/9/2018 10:11

Many of us are long term holders and occasionally topping up on decent pull backs when the market permits. Good news flow coming throughbut not one to day trade or short term trade really. Today I have been accumulating (MSYS) after the results, apart from that pretty quiet today, US markets closed for Labor Day

[netcurtains] 03/9/2018 09:57

I'm still here ID (I have AF). Anyone with a heart condition would be a mug not to own some of these shares if they have the cash.

Lets face it the NHS is quite good with Heart Ops etc etc but if you have a heart condition you'd be nuts if you did not invest to make things even better.

AOR forever!!!

[investordave] 03/9/2018 09:12

And more of the same today by the looks of it.

[investordave] 31/8/2018 12:19

Small sellers exiting. No patience at all. Good riddance.

[investordave] 31/8/2018 09:49

Here we go again...